Harrow, Inc. filings document an ophthalmic pharmaceutical business built around branded products and ImprimisRx, including operating results, stockholder communications and Regulation FD presentations tied to its U.S. commercialization strategy. Current reports disclose material events such as product and business updates, executive appointments and compensation arrangements, the completed Melt Pharmaceuticals acquisition, and capital-structure matters involving senior unsecured notes due 2030.
Proxy materials cover shareholder voting matters, board governance and executive compensation. The filing record also includes disclosures on material agreements, risk-related cautionary statements, and clinical or regulatory topics connected to Harrow's ophthalmic product portfolio.
Randall E. Pollard, the Chief Accounting Officer of Harrow, Inc. (HROW), filed an initial Form 3 reporting that he does not beneficially own any securities of the company. The event requiring the statement is dated 09/01/2025 and the form was signed and filed via attorney in fact Andrew R. Boll on 09/09/2025. The filing serves as the required Section 16 disclosure for an officer but shows no stock ownership or derivative positions to report.
Harrow, Inc. disclosed that it has priced an offering of $250.0 million aggregate principal amount of its 8.625% senior unsecured notes due 2030 in a private transaction. The notes are being offered to qualified institutional buyers in the U.S. under Rule 144A and to certain non-U.S. investors in offshore transactions under Regulation S.
The company announced the pricing through a press release dated September 8, 2025, which is incorporated by reference as an exhibit. The disclosure emphasizes that this communication is not an offer or solicitation to buy or sell securities in any jurisdiction where such activity would be unlawful.
Harrow, Inc. outlined a major financing and strategic plan centered on a proposed private offering of $250.0 million senior unsecured notes due 2030. The company entered a commitment letter with Fifth Third Bank for a new $40.0 million senior secured revolving credit facility, expected to close after the notes offering and secured by substantially all assets, subject to customary conditions.
Harrow intends to use net proceeds from the 2030 notes to redeem its 8.625% Senior Notes due 2026 and 11.875% Senior Notes due 2027, prepay an Oaktree loan, pay related exit costs, and for general corporate purposes. It has issued a conditional full redemption notice for the 2027 notes at 102% of principal plus accrued interest and expects to call the 2026 notes at 100% plus a make-whole and accrued interest, both funded from the offering. Separately, Harrow signed a non-binding indication of interest to acquire the remaining equity in Melt Pharmaceuticals for about $4.3 million upfront plus contingent cash and equity milestones tied to MELT-300 approval, reimbursement and sales.
Harrow, Inc. reported leadership changes and corporate governance updates. The board appointed longtime finance executive Andrew R. Boll, currently Chief Financial Officer and Secretary, to also serve as President, effective August 21, 2025, with no changes to his compensation.
The company also appointed Randall E. Pollard as Chief Accounting Officer, effective September 1, 2025. His offer includes a $400,000 annual base salary, a target cash bonus equal to 40% of salary, relocation support, and eligibility for six months of severance after 12 months of service. The board approved amended and restated bylaws designating the Chief Executive Officer as principal executive officer, clarifying officer roles, updating titles, and making technical edits.
Harrow, Inc. reported stronger product sales and improved operating performance for the quarter and six months ended June 30, 2025. Product sales for the three months were $63,657,000 compared with $48,871,000 a year earlier, and total revenues for the three months were $63,742,000 versus $48,939,000. Gross profit for the quarter was $47,512,000, driving a GAAP net income of $4,995,000 for the three months ended June 30, 2025, compared with a net loss of $6,473,000 in the prior-year quarter.
For the six months ended June 30, 2025, total revenues were $111,573,000 versus $83,526,000 a year earlier and the company reported a net loss of $12,785,000, an improvement from a $20,038,000 loss in the prior-year period. Cash and cash equivalents increased to $52,963,000 and operating activities provided $18,865,000 of cash during the six months. Material near-term financing items exist: the Oaktree Loan ($107,500,000 principal) and the 2026 Notes ($75,000,000) mature in January and April 2026, and management is pursuing refinancing or asset sales but notes there is no assurance of success, stating these maturities could raise substantial doubt about the company’s ability to continue as a going concern.
Harrow Director Perry J. Sternberg received a grant of 7,339 Restricted Stock Units (RSUs) on June 20, 2025, as reported in this Form 4 filing. The RSUs were awarded as compensation for services rendered or to be rendered.
Key terms of the RSU grant:
- Conversion price: $0
- Vesting schedule: Full vesting on the one-year anniversary of the grant date
- Transfer restrictions: Underlying shares cannot be delivered, transferred, or sold until termination of service
- Ownership form: Direct
The transaction was reported by Andrew R. Boll as Attorney in Fact for Perry J. Sternberg on June 24, 2025. This equity grant aligns with common director compensation practices and creates additional alignment between the director's interests and those of shareholders.
Harrow Director Lauren P. Silvernail received a grant of 7,339 Restricted Stock Units (RSUs) on June 20, 2025, as reported in this Form 4 filing. The RSUs were awarded as compensation for services rendered or to be rendered.
Key terms of the RSU grant:
- Conversion price: $0
- Vesting schedule: Full vesting occurs on the one-year anniversary of the grant date
- Transfer restrictions: Underlying shares cannot be delivered, transferred, or sold until termination of service
- Ownership form: Direct
This transaction represents a standard director compensation arrangement, with the RSUs serving as long-term incentive compensation aligned with shareholder interests. The filing was signed by Andrew R. Boll as Attorney in Fact for Lauren P. Silvernail on June 24, 2025.